Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04304066
NA

Research for the Molecular Imaging of the PD-L1 Targeting Tracer

Sponsor: Peking University Cancer Hospital & Institute

View on ClinicalTrials.gov

Summary

To use the molecular probe PET radionuclide (Ga-68 or F-18) WL12 peptide to detect the expression of PD-L1 in the primary and metastatic lesions in patients with solid tumor; to detect the expression heterogeneity of PD-L1 in the lesion and inter-lesions; to observe the change of PD-L1 expression in the course of treatment. To provide an approach for screening patients with high expression of PD-L1, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the Individualized antitumor treatment of targeted drugs.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2019-08-06

Completion Date

2024-12

Last Updated

2024-08-19

Healthy Volunteers

No

Interventions

OTHER

18F-WL12 PET or 68Ga-WL12 PET

WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning

Locations (1)

Shunlian Zhou

Beijing, China